Phase 3 N=271 Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)
Bladder Diseases · Interstitial Cystitis
Primary: Global Response Assessment (GRA) — 74; 61; 61; 75 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=78 Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Chronic Interstitial Cystitis · Bladder Pain Syndrome · Cystitis, Interstitial
Primary: Change in the Genitourinary Pain Index (GUPI) 2 Months — 6.6; 4.8 score on a scale
N/A N=20 Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Mindfulness · Complementary Medicine
Primary: Global Response Assessment (GRA) — 2; 0; 1; 3 participants
N/A N=16 Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Interstitial Cystitis · Pelvic Pain
Primary: Change in Symptom Severity at 4 and 8 Weeks Post-Treatment as Measured by the Total O'Leary-Sant IC Symptom and Problem Index (ICSI/ICPI) Score — -4; -4 units on a scale
N/A N=16 Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of IC/PBS
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Primary Outcome Measure: Percentage of Subjects Improved Global Response Assessment Scale — 4; 3 Participants — p=0.317
N/A N=10 A Pilot Study Investigating the Use of a Therapeutic Wand in Addition to Physiotherapy for Bladder Pain Syndrome
Painful Bladder Syndrome
Primary: Change in O'Leary-Sant Interstitial Cystitis Symptom Index Score — -4.25; -6.2; 0; -1.8 units on a scale
N/A N=40 PTNS Versus Sham Efficacy in Treatment of BPS
Interstitial Cystitis Bladder Pain Syndromes
Primary: Count of Participants With Patient Global Impression of Improvement (PG-I) Score = 1 or 2 — 2; 4 Participants
N/A N=97 Mindfulness and Yoga for Pain With Interstitial Cystitis Evaluation
Interstitial Cystitis
Primary: Number of Participants Designated as "Treatment Responders" Based on Global Response Assessment (GRA) — 31; 10 Participants
N/A N=10 PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Chronic Interstitial Cystitis · Bladder Pain Syndrome
Primary: Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) — 6.70 score on a scale
Phase 1 N=47 Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis/Bladder Pain Syndrome
Primary: Change From Baseline for Worst Bladder Pain/Discomfort Scores Overnight / Over-the-day — -0.7; -1.6; -0.8; -1.7 score on a scale
N/A N=22 Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Efficacy of Acupuncture to Reduce Pain in Women With Interstitial Cystitis/Painful Bladder Syndrome — -2.08; -2.91 score on a scale
Phase 3 N=90 Clinical Trial Comparing Two Bladder Instillations for IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire — -6.7; -5.8 scores on a scale
Phase 4 N=72 Interstitial Cystitis: Examination of the Central Autonomic Network
Interstitial Cystitis/Painful Bladder Syndrome · Myofascial Pelvic Pain
Primary: Total Score on Genitourinary Pain Index (GUPI) Scale — 24.4; 22.2; 2.35; 29.25 score on a scale
Phase 4 N=20 Botox as a Treatment for Interstitial Cystitis in Women
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Chronic Prostatitis Symptom Index (CPSI-F) — 29.6; 35.2 Total CPSI-F
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 3 N=42 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
Cystitis, Interstitial
Primary: IC/BPS Symptoms Change With Overall Global Response Assessment (GRA) — 2; 1 Participants
Phase 2 N=33 PK and Safety of SI-722 in IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Maximum Plasma Concentration (Cmax) for SI-722 — NA; NA; NA; NA ng/mL
Phase 2 N=98 Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
Interstitial Cystitis · Painful Bladder Syndrome
Primary: Global Response Assessment (GRA) Responders at Week 11. — 19; 15 participants
Phase 2 N=65 An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
Cystitis, Interstitial
Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 6.4; 5.9; -2.3; -1.1 units on a scale
Phase 2 N=69 Efficacy and Safety of AQX-1125 in IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in the Average Daily Bladder Pain Score (e-Diary) — 6.4; 6.7; -2.4; -1.4 units on a scale — p=0.061
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
Phase 4 N=25 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis
Interstitial Cystitis
Primary: Change From Baseline Measured as Global Response Assessment (GRA) Score at 6 and 24 Hours — .5; -.1 units on a scale — p=0.688
Phase 4 N=26 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
Overactive Bladder · Urinary Urge Incontinence · Urinary Bladder, Neurogenic
Primary: Change in Bladder Injection Pain — 5; 4; 5 units on a scale — p=0.94
Phase 2 N=131 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
Cystitis, Interstitial · Painful Bladder Syndrome
Primary: Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up — -1.2; -1.5 score on a scale — p=0.505
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 4 N=132 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence
Urinary Bladder, Overactive
Primary: Change in OAB Symptoms Post Pubovaginal Sling Operation — 63; 21; 4 participants — p=0.001
Phase 4 N=100 Overactive Bladder Innovative Therapy Trial (OrBIT)
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 4 N=77 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
Flank Pain · Urinary Bladder, Overactive
Primary: Change in Post-ureteroscopy Stent-induced Pain — 4.61; 3.11 units on a scale